Biomea Fusion, Inc. (BMEA) Stock Analysis & Investment Frameworks
Biomea Fusion, Inc. (BMEA) stock analysis on Invetso. Review Biomea Fusion, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Biomea Fusion, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Biomea Fusion, Inc. Key Financial Metrics
- Market Cap: $40.98M
- Revenue: $N/A
- ROE: -171.19%
- ROIC: -212.95%
- Dividend Yield: N/A
About Biomea Fusion, Inc.
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
Biomea Fusion, Inc. Investment Frameworks
Invetso analyzes Biomea Fusion, Inc. (BMEA) across the following frameworks:
- Biomea Fusion, Inc. 10Y Growth Potential
- Biomea Fusion, Inc. Scenario Analysis
- Biomea Fusion, Inc. Risks & Opportunities
- Biomea Fusion, Inc. Economic Moat
- Biomea Fusion, Inc. Business Model
- Biomea Fusion, Inc. Management
- Biomea Fusion, Inc. SWOT Analysis
- Biomea Fusion, Inc. Porter's 5 Forces
- Biomea Fusion, Inc. PESTLE Analysis
- Biomea Fusion, Inc. ESG Analysis